Ischemic optic neuropathy

Neurological Research

Volumn 30, Issue 8, 2008, Pages 794-800

  Athappilly, Geetha ^a   Pelak, Victoria S ^a   Mandava, Naresh ^a   Bennett, Jeffrey L ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Arteritic ischemic optic neuropathy; Giant cell arteritis; Ischemic optic neuropathy; Non arteritic anterior ischemic optic neuropathy; Posterior ischemic optic neuropathy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BEVACIZUMAB; BRIMONIDINE; C REACTIVE PROTEIN; CORTICOSTEROID; HEPARIN; INFLIXIMAB; LEVODOPA; METHYLPREDNISOLONE; PHENYTOIN; PROTEIN C; SILDENAFIL; STEROID; TUMOR NECROSIS FACTOR ALPHA; VITRONECTIN;

ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ANTITHROMBIN III DEFICIENCY; BLOOD VESSEL BIOPSY; BLOOD VESSEL OCCLUSION; CLINICAL TRIAL; DIPLOPIA; DRUG MEGADOSE; ENZYME DEFICIENCY; ERYTHROCYTE SEDIMENTATION RATE; FLUORESCENCE ANGIOGRAPHY; GIANT CELL ARTERITIS; HALLUCINOSIS; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; INTRAOCULAR HYPOTENSION; ISCHEMIC OPTIC NEUROPATHY; MIDDLE AGED; NERVE DECOMPRESSION; NEUROIMAGING; NON ARTERITIC ISCHEMIC OPTIC NEUROPATHY; OPHTHALMOPLEGIA; OPHTHALMOSCOPY; OPTIC NERVE INJURY; POSTERIOR ISCHEMIC OPTIC NEUROPATHY; REVIEW; RISK FACTOR; THROMBOCYTE COUNT; TREATMENT OUTCOME; UVEITIS; VISUAL IMPAIRMENT;

BLINDNESS; DIAGNOSIS, DIFFERENTIAL; GIANT CELL ARTERITIS; HUMANS; OPTIC DISK; OPTIC NERVE DISEASES; OPTIC NEUROPATHY, ISCHEMIC; VISUAL ACUITY;

EID: 53549116196     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X319107     Document Type: Review

References (68)

1. Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990; 33: 1074-1087
2. Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004; 51: 264-268
3. Salvarani C, Gabriel SE, O'Fallon WM, et al.. The incidence of giant cell arteritis in Olmsted County, Minnesota: Apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 192-194
4. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996; 23: 112-119
5. Narvaez J, Clavaguera MT, Nolla-Sole JM, et al. Lack of association between infection and onset of polymyalgia rheumatica. J Rheumatol 2000; 27: 953-957
6. Elling H, Olsson AT, Elling P. Human parvovirus and giant cell arteritis: A selective arteritic impact? Clin Exp Rheumatol 2000; 18: S12-14
7. Gordon LK, Goldman M, Sandusky H, et al. Identification of candidate microbial sequences from inflammatory lesion of giant cell arteritis. Clin Immunol 2004; 111: 286-296
8. Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199: 173-183
9. Haworth S, Ridgeway J, Stewart I, et al. Polymyalgia rheumatica is associated with both HLA-DRB1*0401 and DRB1*0404. Br J Rheumatol 1996; 35: 632-635
10. Weyand CM, Hunder NN, Hicok KC, et al. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994; 37: 514-520
11. Keltner JL. Giant-cell arteritis. Signs and symptoms. Ophthalmology 1982; 89: 1101-1110
12. Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell arteritis: Validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285-296
13. Salvarani C, Giannini C, Miller DV, et al. Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum 2006; 55: 985-989
14. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002; 80: 355-367
15. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000; 79: 283-292
16. Bandini F, Benedetti L, Ceppa P, et al. Uveitis as a presenting sign of giant cell arteritis. J Neuroophthalmol 2005; 25: 247-248
17. Costello F, Zimmerman MB, Podhajsky PA, et al. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol 2004; 14: 245-257
18. Mack HG, O'Day J, Currie JN. Delayed choroidal perfusion in giant cell arteritis. J Clin Neuroophthalmol 1991; 11: 221-227
19. Siatkowski RM, Gass JD, Glaser JS, et al. Fluorescein angiography in the diagnosis of giant cell arteritis. Am J Ophthalmol 1993; 115: 57-63
20. Danesh-Meyer HV, Savino PJ, Eagle RC, Jr, et al. Low diagnostic yield with second biopsies in suspected giant cell arteritis. J Neuroophthalmol 2000; 20: 213-215
21. Liu GT, Glaser JS, Schatz NJ, et al. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994; 101: 1779-1785
22. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54: 3310-3318
23. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. J Rheumatol 2000; 27: 1484-1491
24. Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: New light on old controversies. Ophthalmologica 2003; 217: 239-259
25. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005; 112: 1098-1103
26. Buono LM, Foroozan R, de Virgiliis M, et al. Heparin therapy in giant cell arteritis. Br J Ophthalmol 2004; 88: 298-301
27. Torrente SV, Guerri RC, Perez-Garcia C, et al. Amaurosis in patients with giant cell arteritis: Treatment with anti-tumour necrosis factor-alpha. Intern Med J 2007; 37: 280-281
28. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. Ann Intern Med 2007; 146: 621-630
29. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: A randomized trial. Ann Intern Med 2007; 146: 631-639
30. Hayreh SS. The blood supply of the optic nerve head and the evaluation of it - myth and reality. Prog Retin Eye Res 2001; 20: 563-593
31. Arnold AC, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 117: 222-230
32. Hayreh SS. Anterior ischemic optic neuropathy. Arch Neurol 1981; 38: 675-678
33. Hayreh SS, Podhajsky P, Zimmerman MB. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica 1999; 213: 76-96
34. Mojon DS, Hedges TR 3rd, Ehrenberg B, et al. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol 2002; 120: 601-605
35. Jacobson DM, Vierkant RA, Belongia EA. Nonarteritic anterior ischemic optic neuropathy. A case-control study of potential risk factors. Arch Ophthalmol 1997; 115: 1403-1407
36. Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1999; 106: 739-742
37. Salomon O, Rosenberg N, Steinberg DM, et al. Nonarteritic anterior ischemic optic neuropathy is associated with a specific platelet polymorphism located on the glycoprotein Ibalpha gene. Ophthalmology 2004; 111: 184-188
38. The Ischemic Optic Neuropathy Decompression Trial Research Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114: 1366-1374
39. Deramo VA, Sergott RC, Augsburger JJ, et al. Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. Ophthalmology 2003; 110: 1041-1046
40. Weger M, Stanger O, Deutschmann H, et al. Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy. Br J Ophthalmol 2001; 85: 803-806
41. Palmowski-Wolfe AM, Denninger E, Geisel J, et al. Antiphospholipid antibodies in ocular arterial and venous occlusive disease. Ophthalmologica 2007; 221: 41-46
42. Bertram B, Remky A, Arend O, et al. Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Ger J Ophthalmol 1995; 4: 332-335
43. Srinivasan S, Fern A, Watson WH, et al. Reversal of nonarteritic anterior ischemic optic neuropathy associated with coexisting primary antiphospholipid syndrome and Factor V Leiden mutation. Am J Ophthalmol 2001; 131: 671-673
44. Lee AG. Prothrombotic and vascular risk factors in nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1999; 106: 2231
45. Chan J. Bilateral non-arteritic ischemic optic neuropathy associated with pegylated interferon for chronic hepatitis C. Eye 2007; 10: 1038
46. Pomeranz HD, Smith KH, Hart WM, Jr, et al. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109: 584-587
47. Hayreh SS, Podhajsky PA, Zimmerman B. Ipsilateral recurrence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 2001; 132: 734-742
48. Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: Report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002; 134: 317-328
49. Botelho PJ, Johnson LN, Arnold AC. The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1996; 121: 450-451
50. Johnson LN, Guy ME, Krohel GB, et al. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2000; 107: 521-526
51. Kollarits CR, McCarthy RW, Corrie WS, et al. Norepinephrine therapy of ischemic optic neuropathy. J Clin Neuroophthalmol 1981; 1: 283-288
52. Wilhelm B, Ludtke H, Wilhelm H. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): A 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 2006; 244: 551-558
53. Keltner JL, Becker B, Gay AJ, et al. Effect of diphenylhydantoin in ischemic optic neuritis. Trans Am Ophthalmol Soc 1972; 70: 113-130
54. Hayreh SS, Zimmerman MB. Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1107-1121
55. The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 1995; 273: 625-632
56. Arnold AC, Hepler RS, Lieber M, et al. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1996; 122: 535-541
57. Kim TW, Kim DM, Park KH, et al. Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia. Korean J Ophthalmol 2002; 16: 1-7
58. van Bruggen N, Thibodeaux H, Palmer JT, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 1999; 104: 1613-1620
59. Bennet JL, Thomas S, Olson JL, et al. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol 2007; 27: 238-240
60. Beck RW, Hayreh SS, Podhajsky PA, et al. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997; 123: 212-217
61. Sadda SR, Nee M, Miller NR, et al. Clinical spectrum of posterior ischemic optic neuropathy. Am J Ophthalmol 2001; 132: 743-750
62. Hayreh SS. Posterior ischaemic optic neuropathy: Clinical features, pathogenesis, and management. Eye 2004; 18: 1188-1206
63. Chang SH, Miller NR. The incidence of vision loss due to perioperative ischemic optic neuropathy associated with spine surgery: The Johns Hopkins Hospital Experience. Spine 2005; 30: 1299-1302
64. Myers MA, Hamilton SR, Bogosian AJ, et al. Visual loss as a complication of spine surgery. A review of 37 cases. Spine 1997; 22: 1325-1329
65. Shaked G, Gavriel A, Roy-Shapira A. Anterior ischemic optic neuropathy after hemorrhagic shock. J Trauma 1998; 44: 923-925
66. Buono LM, Foroozan R, Savino PJ, et al. Posterior ischemic optic neuropathy after hemodialysis. Ophthalmology 2003; 110: 1216-1218
67. Hayreh SS. Anterior ischemic optic neuropathy. VIII. Clinical features and pathogenesis of post-hemorrhagic amaurosis. Ophthalmology 1987; 94: 1488-1502
68. Winkelmayer WC, Eigner M, Berger O, et al. Optic neuropathy in uremia: An interdisciplinary emergency. Am J Kidney Dis 2001; 37: E23